Table 7.
Reported neuroprotective and regenerative effects of RNA and lipid biologics in preclinical studies.
| Outcome | Anti-LINGO-1 shRNA/siRNA | Anti-NgR1 siRNA | MicroRNA-146a mimic | E6020 | GD1a ganglioside |
|---|---|---|---|---|---|
| Increased viability of OPC and/or OLG | ✓ | ||||
| Preserved quantity, function, or integrity of neurons/axons | ✓ | ||||
| Protected against myelin loss and/or atrophy and lesions | ✓✓ | ✓✓ | ✓ | ||
| Reduced CNS oxidative stress, apoptosis, or cellular dysfunction | ✓ | ||||
| Suppressed inflammatory microglial and/or astrocyte activation | ✓ | ✓ | |||
| Promoted NPC/OPC proliferation or differentiation | ✓✓ | ✓ | ✓ | ||
| Induced formation of new myelin | ✓ | ✓ | |||
| Increased clearance of axonal myelin debris | ✓ | ||||
| Suppressed myelin inhibitory factors | ✓✓ | ✓✓ | ✓ | ||
| Improved neurological function (physical or cognitive) | ✓✓ | ✓ | ✓ | ||
| Animal models/clinical studies | EtBr and EAE | LPC | EAE | LPC | Cuprizone |
EAE: experimental autoimmune encephalomyelitis; EtBr: ethidium bromide; LPC: lysophosphatidylcholine; NgR1: Nogo-A receptor 1; NPC: neural precursor cell; OLG: oligodendrocyte; OPC: oligodendrocyte precursor cell; shRNA: short hairpin RNA; siRNA: short interfering RNA.
Each check (✓) represents an observed outcome from an individual study.